Provided by Tiger Fintech (Singapore) Pte. Ltd.

VYNE Therapeutics Inc.

0.3175
-0.0050-1.55%
Post-market: 0.3107-0.0068-2.14%19:53 EDT
Volume:1.27M
Turnover:403.47K
Market Cap:8.09M
PE:-0.35
High:0.3268
Open:0.3210
Low:0.3100
Close:0.3225
52wk High:4.30
52wk Low:0.3100
Shares:25.47M
Float Shares:22.38M
Volume Ratio:0.62
T/O Rate:5.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9036
EPS(LYR):-0.9353
ROE:-67.73%
ROA:-40.53%
PB:0.21
PE(LYR):-0.34

Loading ...

Vyne Therapeutics Inc - Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-Vasi50 and F-Vasi75

THOMSON REUTERS
·
Jul 30

Vyne Therapeutics Inc - Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib

THOMSON REUTERS
·
Jul 30

Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study

TIPRANKS
·
Jul 09

VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating

TIPRANKS
·
Jul 03

BRIEF-Vyne Therapeutics Provides Program Update On Oral BET Inhibitor VYN202

Reuters
·
Jul 02

VYNE Therapeutics provides program update on VYN202 following clinical hold

TIPRANKS
·
Jul 02

VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating

TIPRANKS
·
May 09

Vyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

VYNE Therapeutics reports Q1 EPS (20c) vs (15c) last year

TIPRANKS
·
May 08

VYNE Therapeutics Q1 EPS $(0.20) Beats $(0.29) Estimate, Sales $202.00K Beat $50.00K Estimate

Benzinga
·
May 08

BRIEF-VYNE Therapeutics Q1 Basic EPS USD -0.2

Reuters
·
May 08

Vyne Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
May 05

Vyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 25

VYNE Says FDA Halted Psoriasis Drug Trial After Signs of Toxicity Found; Shares Down Pre-Bell

MT Newswires Live
·
Apr 25

VYNE Therapeutics Provides Update on VYN202 Program

GlobeNewswire
·
Apr 25

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire
·
Mar 20

VYNE Therapeutics Reports Progress in Clinical Trials

TIPRANKS
·
Mar 08

Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)

TIPRANKS
·
Mar 07

VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
Mar 07

Buy Rating for VYNE Therapeutics Driven by Strong Financial Health and Promising Pipeline Developments

TIPRANKS
·
Mar 07